CYP2C8

Source: Wikipedia, the free encyclopedia.
CYP2C8
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_000770
NM_001198853
NM_001198854
NM_001198855
NM_030878

NM_010003
NM_001373937

RefSeq (protein)

NP_000761
NP_001185782
NP_001185783
NP_001185784

NP_034133
NP_001360866

Location (UCSC)Chr 10: 95.04 – 95.07 MbChr 19: 39.5 – 39.56 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Cytochrome P4502C8 (CYP2C8) is a member of the

polyunsaturated fatty acids, e.g. arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, and Linoleic acid to their biologically active epoxides.[5]

Ligands

Following is a table of selected

of 2C8.

Inhibitors of CYP2C8 can be classified by their potency, such as:

Selected inducers, inhibitors and substrates of CYP2C8
Substrates Inhibitors Inducers

Strong

Moderate

Unspecified potency

  • antidiabetic
    )
  • leukotriene receptor antagonist
    )
  • antiinflammatory
    )

Unspecified potency

Where classes of agents are listed, there may be exceptions within the class.

Epoxygenase activity

CYP2C8 also possesses epoxygenase activity: it is one of the principal enzymes responsible for attacking various long-chain polyunsaturated fatty acids at their double (i.e. alkene) bonds to form epoxide products that act as signaling agents. It metabolizes: 1) arachidonic acid to various epoxyeicosatrienoic acids (also termed EETs); 2) linoleic acid to 9,10-epoxy octadecenoic acids (also termed vernolic acid, linoleic acid 9:10-oxide, or leukotoxin) and 12,13-epoxy-octadecenoic (also termed coronaric acid, linoleic acid 12,13-oxide, or isoleukotoxin); 3) docosahexaenoic acid to various epoxydocosapentaenoic acids (also termed EDPs); and 4) eicosapentaenoic acid to various epoxyeicosatetraenoic acids (also termed EEQs).[9][10][11]

Along with CYP2C8, CYP2C9, CYP2C19, CYP2J2, and possibly CYP2S1 are the main producers of EETs and, very likely, EEQs, EDPs, and the epoxides of linoleic acid.[12][13]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000138115Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025003Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 21945326
    .
  6. ^ a b c d e f g h i j k l m n o Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Indiana University School of Medicine. Retrieved on July 2011
  7. .
  8. ^ Product Information: PLAVIX(R) oral tablets, clopidogrel bisulfate oral tablets. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership (per FDA), Bridgewater, NJ, 2019. https://packageinserts.bms.com/pi/pi_plavix.pdf Archived 2021-06-12 at the Wayback Machine
  9. S2CID 39465144
    .
  10. .
  11. .
  12. .
  13. .

External links

Further reading

This page is based on the copyrighted Wikipedia article: CYP2C8. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy